Antimicrobial peptides for tackling cystic fibrosis related bacterial infections: A review.

Anti-Bacterial Agents / pharmacology Antimicrobial Peptides Bacterial Infections / drug therapy Cystic Fibrosis / drug therapy Drug Resistance, Microbial Humans Microbial Sensitivity Tests
Antibiotic Resistance Antimicrobial Peptides Biofilm Cystic Fibrosis Drug Delivery Nanoparticles

Journal

Microbiological research
ISSN: 1618-0623
Titre abrégé: Microbiol Res
Pays: Germany
ID NLM: 9437794

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 15 06 2022
revised: 28 07 2022
accepted: 29 07 2022
pubmed: 10 8 2022
medline: 17 8 2022
entrez: 9 8 2022
Statut: ppublish

Résumé

Antibiotic resistance is a serious health and social problem that will have a substantial impact in the coming years on the world health and economy. Thus, the increasing demand for innovative antibiotics, has prompted many researchers in the medical, microbiological, and biochemical fields to exploit the properties of antimicrobial peptides (AMPs). When properly used, designed, and conveyed, AMPs can really represent a valid alternative to conventional drugs especially in situations that are particularly difficult to treat such as chronic infections found in Cystic Fibrosis (CF) patients. In this review we focused on the applications of AMPs in the specific field of CF, illustrating different types of peptides from natural, naturally modified, synthetic as well as the different strategies used to overcome the barriers, and the physiological conditions in which AMPs must operate.

Identifiants

DOI: 10.1016/j.micres.2022.127152 PMID: 35944357
pubmed: 35944357
pii: S0944-5013(22)00192-6
doi: 10.1016/j.micres.2022.127152
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antimicrobial Peptides 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

127152

Informations de copyright

Copyright © 2022 Elsevier GmbH. All rights reserved.

Auteurs

Francesca Bugli (F)

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.

Cecilia Martini (C)

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.

Maura Di Vito (M)

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.

Margherita Cacaci (M)

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.

Daniele Catalucci (D)

IRCCS Humanitas Research Hospital, Rozzano (MI), Italy and Institute of Genetic and Biomedical Research (IRGB) - UoS Milan, National Research Council (CNR), Milan, Italy.

Alessandro Gori (A)

Institute of Chemical Sciences and Technologies "G. Natta" (SCITEC) - UoS Milan, National Research Council (CNR), Milan, Italy.

Michele Iafisco (M)

Institute of Science and Technology for Ceramics (ISTEC), National Research Council (CNR), Faenza (RA), Italy. Electronic address: michele.iafisco@istec.cnr.it.

Maurizio Sanguinetti (M)

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: maurizio.sanguinetti@unicatt.it.

Alberto Vitali (A)

Institute of Chemical Sciences and Technologies "G. Natta" (SCITEC) - UoS Rome, National Research Council (CNR), Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antimicrobial peptides for tackling cystic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides antimicrobiens › Antimicrobial peptides for tackling cystic...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Antimicrobial peptides for tackling cystic...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies néonatales › Mucoviscidose › Antimicrobial peptides for tackling cystic...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Antimicrobial peptides for tackling cystic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Antimicrobial peptides for tackling cystic...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Antimicrobial peptides for tackling cystic...